Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 0933 • ACR Convergence 2025
Spatial Transcriptomics Reveal Altered Immune Dynamics Regulating Placental Development In a Humanized-TLR8 Mouse Model of Spontaneous Anti-Phospholipid Antibody Induced Pregnancy Loss
Yunwei Xia¹, Paul Hoover², Arnon Arazi³ and Anne Davidson¹, ¹Feinstein Institutes for Medical Research, Manhasset, NY, ²Brigham and Women's Hospital, Boston, MA, ³Feinstein Institutes for Medical Research, Acton, MA
Background/Purpose: TLR8 has been implicated in adverse outcomes of human pregnancy. We previously reported a mouse model of spontaneous aPL-induced pregnancy loss in Sle1 mice…
Abstract Number: 0137 • ACR Convergence 2025
Landscape of Primary Antiphospholipid Syndrome: Clinical Spectrum, Serology, and Predictors of Damage in a Single Center Cohort of 233 Patients
RITESH KUMAR MISHRA¹, SUBIN PHILIP², JAIDEV MENON², RIZWANA NAUSHAD², AISHWARYA GOPAL³, CHRISTINA MARIASELVAM², Chengappa Kavadichanda², Molly mary Thabah³ and VIR SINGH NEGI², ¹JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, Bhubaneswar, India, ²JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, Puducherry, India, ³JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, India
Background/Purpose: Primary Antiphospholipid Syndrome (APS) a systemic autoimmune prothrombotic disorder with long-term consequences. While secondary APS is well studied, large real-world cohorts of primary APS…
Abstract Number: 0121 • ACR Convergence 2025
The Prevalence and Clinical Significance of IgA Anticardiolipin and Anti-β2-Glycoprotein-I Antibody Isotypes in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Registry
Emre Sahin¹, Yu (Ray) Zuo², Danieli Andrade³, Maria Tektonidou⁴, Vittorio Pengo⁵, Massimo Radin⁶, Chary López pedrera⁷, Diana Paredes-Ruiz⁸, H Michael Belmont⁹, Paul Fortin¹⁰, Denis WAHL¹¹, Ware Branch¹², Maria Gerosa¹³, Guilherme Ramires de Jesus¹⁴, Tatsuya Atsumi¹⁵, Maria Efthymiou¹⁶, Angela Tincani¹⁷, Esther Rodriguez-Almaraz¹⁸, Michelle Petri¹⁹, Ricard Cervera²⁰, Rohan Willis²¹, Katrien Devreese²², Maria Laura Bertolaccini²³, Hannah Cohen²⁴, Jason S. Knight² and Doruk Erkan¹, ¹Hospital for Special Surgery, New York, NY, ²University of Michigan, Ann Arbor, MI, ³University of Sao Paulo, São Paulo, São Paulo, Brazil, ⁴National and Kapodistrian University of Athens, Athens, Greece, ⁵Padova University Hospital, Padova, Italy, ⁶University of Turin, Turin, Turin, Italy, ⁷Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁸Biobizkaia Health Research Institute, Barakaldo, Spain, ⁹NYU School of Medicine, New York, NY, ¹⁰Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹¹University of Lorraine, Nancy, France, ¹²University of Utah Health Sciences Center, Salt Lake City, UT, ¹³University of Milan, Milano, Italy, ¹⁴Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Rio de Janeiro, Brazil, ¹⁵Hokkaido University, Sapporo, Japan, ¹⁶University College London, London, United Kingdom, ¹⁷ASST Spedali Civili-University of Brescia, Gussago, Brescia, Italy, ¹⁸Hospital Universitario ¹² de Octubre, Madrid, Spain, ¹⁹Johns Hopkins University School of Medicine, Timonium, MD, ²⁰Hospital Clinic Barcelona, Barcelona, Spain, ²¹University of Texas Medical Branch, Galveston, TX, ²²Ghent University, Gent, Belgium, ²³King's College London, London, United Kingdom, ²⁴University College London Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: The 2023 ACR/EULAR Antiphospholipid Syndrome (APS) Classification Criteria (CC) focus on IgG and IgM anticardiolipin (aCL) and anti-β2-glycoprotein-I antibodies (aβ2GPI). IgA isotypes were excluded…
Abstract Number: 0710 • ACR Convergence 2025
Vascular Events in Systemic Sclerosis Patients with Anti-Phospholipid Antibodies
Vivian Shing¹, Emily Thompson², Emma Terwilliger³, Simran Ravindra Nimal⁴, Alejandro Diaz Arumir Vergara², Michael Pham⁴ and Vivek Nagaraja⁴, ¹Mayo Clinic Alix School of Medicine, Scottsdale, AZ, ²Mayo Clinic, Scottsdale, ³Mayo Clinic Alix School of Medicine, Scottsdale, ⁴Mayo Clinic, Scottsdale, AZ
Background/Purpose: APS is a pro-thrombotic autoimmune condition often associated with other systemic autoimmune rheumatic diseases (SARDs), most notably SLE. The link between aPL positivity and…
Abstract Number: 0136 • ACR Convergence 2025
Beyond Thrombosis: Histological Spectrum, Predictors and Outcomes of Renal Involvement in Primary Antiphospholipid Syndrome: A Single-Centre Cohort Study
RITESH KUMAR MISHRA¹, SUBIN PHILIP², RIZWANA NAUSHAD², AISHWARYA GOPAL³, Chengappa Kavadichanda², CHRISTINA MARIASELVAM², RAJESH N G², Molly mary Thabah³ and VIR SINGH NEGI², ¹JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, Bhubaneswar, India, ²JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, Puducherry, India, ³JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, India
Background/Purpose: Renal involvement in primary APS is underrecognized and histologically diverse, encompassing both vascular and glomerular pathology. We aimed to describe the histopathology, outcomes of…
Abstract Number: 0119 • ACR Convergence 2025
Thrombin Generation Assays Inform Hypercoagulability Mediated by Antiphospholipid Antibodies in Children with Systemic Lupus Erythematosus
Elizabeth Sloan¹, Blake Baay², Lynnette Walters², Paola Sparagana², Kristina Ciaglia¹, Simrat Morris¹, Julie Fuller¹, Lorien Nassi¹, Tracey Wright¹ and Ayesha Zia³, ¹UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ²Scottish Rite for Children, Dallas, TX, ³UT Southwestern and Children's Medical Center, Dallas, TX
Background/Purpose: In pediatric systemic lupus erythematosus (SLE), antiphospholipid antibodies (aPL) are independent risk factors for thrombosis. However, data are limited on how aPL impact hypercoagulability.…
Abstract Number: 0600 • ACR Convergence 2025
Toward a Consensus-Based Definition of Difficult-to-Treat Systemic Lupus Erythematosus: A Multinational Survey of Clinicians from the MENA Region
Ahlam Almarzooqi¹, Sarah Al Qassimi², Nelly Ziade³, Mohammed Omair⁴, Samar Al emadi⁵, FARIDA ALBALUSHI⁶, Waleed Hafiz⁷, Hiba Khogali⁸, Saadeya Naji⁹, Suzan Attar¹⁰, Khalid Alnaqbi¹¹ and Rajaie Namas¹², ¹Emirates Health Services, Sharjah, United Arab Emirates, ²Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, ³Department of Rheumatology, Saint-Joseph University and Hotel-Dieu de France, Beirut, Lebanon, ⁴King Saud university, Riyadh, Saudi Arabia, ⁵Hamad medical corporation, Doha, Qatar, ⁶Royal hospital, Dubia, United Arab Emirates, ⁷Umm Al-Qura university, Makkah, Makkah, Saudi Arabia, ⁸Madinat Zayed Hospital , Al Dhafra hospitals, Abu Dhabi, Abu Dhabi, United Arab Emirates, ⁹Salmaniya medical complex, BAHRAIN, Al Asimah, Bahrain, ¹⁰King Abdulaziz University, Saudi Arabia, Jeddah, Saudi Arabia, ¹¹Sheikh Tahnoon Medical city, Al Ain, United Arab Emirates, ¹²Cleveland Clinic Abu Dhabi, Detroit, MI
Background/Purpose: Difficult-to-treat systemic lupus erythematosus (D2T-SLE) presents a major challenge due to disease heterogeneity and a lack of unified classification. While the D2T concept has…
Abstract Number: 0135 • ACR Convergence 2025
Rituximab in Antiphospholipid Syndrome: aPL Titer Decline and Clinical Outcomes
Omer Uludag¹, Soner Altın², Gamze Kemec², yasemin yalcinkaya³, Ahmet Gul³, Murat Inanc³ and Bahar Artim Esen⁴, ¹Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey, ³Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Istanbul, Turkey, ⁴Istanbul University, Istanbul, Istanbul, Turkey
Background/Purpose: Rituximab treatment has been shown to be effective in non-thrombotic manifestations of APS and refractory catastrophic APS (CAPS). However, there are conflicting results regarding…
Abstract Number: 0120 • ACR Convergence 2025
The Prevalence and Clinical Significance of Heritable Thrombophilia in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry
Emre Sahin¹, Maria Efthymiou², Danieli Andrade³, Megan Barber⁴, Maria Tektonidou⁵, Vittorio Pengo⁶, Massimo Radin⁷, Jose Pardos-Gea⁸, MARIA ANGELES AGUIRRE ZAMORANO⁹, Nina Kello¹⁰, Diana Paredes-Ruiz¹¹, H Michael Belmont¹², Paul Fortin¹³, Denis WAHL¹⁴, Ware Branch¹⁵, Maria Gerosa¹⁶, Guilherme Ramires de Jesus¹⁷, Zhuoli Zhang¹⁸, Tatsuya Atsumi¹⁹, Giulia Pazzola²⁰, Laura Andreoli²¹, Ali Duarte-Garcia²², Esther Rodriguez-Almaraz²³, Michelle Petri²⁴, Ricard Cervera²⁵, Bahar Artim Esen²⁶, Guillermo Pons-Estel²⁷, Hui Shi²⁸, Jason S. Knight²⁹, Rohan Willis³⁰, Maria Laura Bertolaccini³¹, Hannah Cohen³² and Doruk Erkan¹, ¹Hospital for Special Surgery, New York, NY, ²University College London, London, United Kingdom, ³University of Sao Paulo, São Paulo, São Paulo, Brazil, ⁴Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵National and Kapodistrian University of Athens, Athens, Greece, ⁶Padova University Hospital, Padova, Italy, ⁷University of Turin, Turin, Turin, Italy, ⁸Vall d’Hebron University Hospital, Barcelona, Spain, ⁹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ¹⁰Northwell Health, Brooklyn, NY, ¹¹Biobizkaia Health Research Institute, Barakaldo, Spain, ¹²NYU School of Medicine, New York, NY, ¹³Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹⁴University of Lorraine, Nancy, France, ¹⁵University of Utah Health Sciences Center, Salt Lake City, UT, ¹⁶University of Milan, Milano, Italy, ¹⁷Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Rio de Janeiro, Brazil, ¹⁸Peking University First Hospital, Beijing, Beijing, China (People's Republic), ¹⁹Hokkaido University, Sapporo, Japan, ²⁰Rheumatology Unit, Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy, ²¹University of Brescia, Brescia, Brescia, Italy, ²²Mayo Clinic, Rochester, MN, ²³Hospital Universitario ¹² de Octubre, Madrid, Spain, ²⁴Johns Hopkins University School of Medicine, Timonium, MD, ²⁵Hospital Clinic Barcelona, Barcelona, Spain, ²⁶Istanbul University, Istanbul, Istanbul, Turkey, ²⁷Centro Regional de Enfermedades Autoinmunes y Reumáticas, GO-CREAR, Rosario, Argentina, Rosario, Argentina, ²⁸Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic), ²⁹University of Michigan, Ann Arbor, MI, ³⁰University of Texas Medical Branch, Galveston, TX, ³¹King's College London, London, United Kingdom, ³²University College London Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: Although antiphospholipid antibodies (aPL) are well-established risk factors for thrombosis, heritable thrombophilias (HT) are also associated with venous thromboembolism (VTE). The latter includes deficiencies…
Abstract Number: 0860 • ACR Convergence 2025
Activated protein C resistance and protein C antibodies in the antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository
Maria Efthymiou¹, Ibrahim Tohidi-Esfahani², Veronica Venturelli¹, Maria Tektonidou³, Vittorio Pengo⁴, Diana Parades-Ruiz⁵, Ware Branch⁶, Maria Gerosa⁷, Cecilia Nalli⁸, Esther Rodriguez Almaraz⁹, Michelle Petri¹⁰, Ricard Cervera¹¹, Olga Amengual¹², Danieli Andrade¹³, Rohan Willis¹⁴, Maria Laura Bertolaccini¹⁵, Doruk Erkan¹⁶ and Hannah Cohen¹⁷, ¹University College London, London, United Kingdom, ²University of Sydney, Syndey, Australia, Sydney, Australia, ³National and Kapodistrian University of Athens, Athens, Greece, ⁴Padova University Hospital, Padova, Italy, ⁵Biobizkaia Health Research Institute, Barakaldo, Spain, Barakaldo, Spain, ⁶University of Utah Health Sciences Center, Salt Lake City, UT, ⁷University of Milan, Milano, Italy, ⁸ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ⁹Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Spain, ¹⁰Johns Hopkins University School of Medicine, Timonium, MD, ¹¹Hospital Clinic Barcelona, Barcelona, Spain, ¹²Hokkaido University Graduate School of Medicine, Sapporo, Japan, Sapporo, Japan, ¹³University of Sao Paulo, São Paulo, São Paulo, Brazil, ¹⁴University of Texas Medical Branch, Galveston, TX, ¹⁵King's College London, London, United Kingdom, ¹⁶Hospital for Special Surgery, New York, NY, ¹⁷University College London Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: Dysregulation in the protein C anticoagulant pathway, more specifically acquired resistance to activated protein C (APCr) and antibodies against protein C (anti-PC), has been…
Abstract Number: 0134 • ACR Convergence 2025
Neutrophil Gasdermin D Pores as Potential Therapeutic Targets in APS-Associated Thromboinflammation
NaveenKumar Somanathapura¹, Thalia Newman¹, Chao Liu², Srilakshmi Yalavarthi³, Cyrus Sarosh⁴, Jacqueline Madison¹, Ajay Tambralli¹, Yu (Ray) Zuo¹ and Jason S. Knight¹, ¹University of Michigan, Ann arbor, MI, ²University of Michigan, Superior Charter Twp, MI, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, ⁴University of Michigan, Temperance, MI
Background/Purpose: Emerging evidence implicates neutrophil activation and neutrophil extracellular trap (NET) formation (i.e., NETosis) in amplifying APS-associated thromboinflammation. Gasdermin D (GSDMD), a substrate of inflammatory…
Abstract Number: 0118 • ACR Convergence 2025
Single-cell RNA sequencing of skin reveals vascular dysregulation in antiphospholipid syndrome
Ecem Sevim¹, Sumith Panicker², Gustaf Wigerblad³, Stefania Dell'orso⁴, Sharon Osgood², Leslie Castelo-Soccio⁵, Keisuke Nagao⁶ and Yogendra Kanthi⁷, ¹NIAMS/NIH, Bethesda, MD, ²NHLBI/NIH, Bethesda, ³National Institutes of Health, Stockholm, Sweden, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁵NIAMS/NIH, Bethesda, ⁶NIAMS, Bethesda, MD, ⁷National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune thromboinflammatory disorder defined by persistent antiphospholipid antibodies (aPL) and characterized clinically by macrovascular thrombosis, microvascular disease, and…
Abstract Number: 0859 • ACR Convergence 2025
Trophoblast Dysfunction and Placental Alterations in a Mouse Model of Antiphospholipid Syndrome: The Potential Role of Neutrophil Extracellular Traps
Bruna Mazetto Fonseca¹, Srilakshmi Yalavarthi², Katarina Kmetova², NaveenKumar Somanathapura³, Cyrus Sarosh⁴, Kavya Sugur⁵, Wenying Liang⁶, Yu (Ray) Zuo³, Richard W. Lieberman⁶ and Jason S. Knight³, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, ³University of Michigan, Ann arbor, MI, ⁴University of Michigan, Temperance, MI, ⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, ⁶University of Michigan, Ann arbor
Background/Purpose: Neutrophil extracellular traps (NETs) are webs of chromatin and proteases (e.g., neutrophil elastase) that have been implicated in antiphospholipid syndrome (APS)-associated thrombosis; however, their…
Abstract Number: 0133 • ACR Convergence 2025
Differences in cardiovascular risk factor control between primary and systemic lupus erythematosus-related antiphospholipid syndrome in a multiethnic cohort of 1003 patients with antiphospholipid syndrome: the SUrvey of cardiovascular disease Risk Factors (SURF) in SLE and APS project
Eleana Bolla¹, Anne Grete Semb², Michelle Petri³, Petros Sfikakis⁴, Bahar Artim Esen⁵, Gabriela Hernandez-Molina⁶, Eric Hachulla⁷, Haner Direskeneli⁸, George Karpouzas⁹, Marta Mosca¹⁰, Mohit Goyal¹¹, Nathalie Costedoat-Chalumeau¹², Angela Tincani¹³, Ayten Yazici¹⁴, Karoline Lerang¹⁵, Anne Troldborg¹⁶, Sofia Ajeganova¹⁷, Tatiana Popkova¹⁸, Elisabet Svenungsson¹⁹, Nikos Pantazis²⁰ and Maria Tektonidou²¹, ¹Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece, ²Preventive Cardio-Rheuma clinic, Dept Rheum, Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴NKUA - SCHOOL OF MEDICINE, Athens, Greece, ⁵Istanbul University, Istanbul, Istanbul, Turkey, ⁶Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Federal District, Mexico, ⁷University of Lille, LILLE, France, ⁸Marmara University, ISTANBUL, Turkey, ⁹Harbor-UCLA Medical Center, Torrance, CA, ¹⁰University of Pisa, Pisa, Pisa, Italy, ¹¹CARE Pain & Arthritis Centre, Udaipur, Rajasthan, India, ¹²Inserm DR Paris ⁵, Paris, France, ¹³ASST Spedali Civili-University of Brescia, Gussago, Brescia, Italy, ¹⁴Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey, ¹⁵Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ¹⁶Aarhus University Hospital, Aarhus, Denmark, ¹⁷Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden, ¹⁸V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ¹⁹Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ²⁰Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece, ²¹National and Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Cardiovascular disease (CVD) in antiphospholipid syndrome (APS) is driven by antiphospholipid antibody-mediated immunothrombotic mechanisms and traditional cardiovascular risk factors (CVRFs). Although the EULAR recommendations…
Abstract Number: 0117 • ACR Convergence 2025
Are Thrombotic or Obstetric Events Associated with Additional Clinical Domains in Triple Antiphospholypid Syndrome?
Cristina Rocamora-Gisbert¹, Francina salabert-Carreras², Raquel Ugena-García³, Cristina Calomarde-Gómez³, Clara Churtichaga Domenech², Judith Vidal-Ripoll², Laia Gifre-Sala², Agueda Prior-Español², Annika Nack¹, Susana Holgado⁴, Maria Aparicio¹, Melania Martínez-Morillo², LOURDES MATEO SORIA⁵, Anne Riveros frutos¹, Ivette Casafont-Solé³ and Judit Font-Urgelles³, ¹Hospital Germans Trias i Pujol, Barcelona, Spain, ²Hospital Germans Trias i Pujol, Barcelona, ³Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁴Hospital Germans Trias i Pujol, Barcelona, Catalonia, Spain, ⁵HOSPITAL GERMANS TRIAS I PUJOL, BADALONA, Spain
Background/Purpose: It is known that triple positive antiphospholipid syndrome (APS-TP) is related to an increased presence of thrombotic and obstetric manifestations. Triple positivity is referred…

1
2
3
…
23
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].